Sanjeev Kumar

Managing Director

India’s pharmaceutical industry is witnessing a decisive shift towards specialised therapies, stronger quality oversight and more agile market models. While manu­facturing capacity remains central to the sector’s growth, the ability to identify unmet therapeutic needs, source dependable formulations and build sustained relation­ships with healthcare professionals is becoming equally important. This is particularly relevant in segments such as neuropsychiatry, where changing healthcare needs are creating demand for focused product portfolios and deep­er market engagement.

Wilwin Laboratories India Private Limited has aligned its growth with this evolving landscape. Established in 2007 and led by Managing Director Sanjeev Kumar, the company has evolved from a general pharmaceutical portfolio to establish a strong focus on neuro and psychiatric therapies. Operating through a third-party manufacturing model, Wilwin combines quality-conscious product sourcing with an extensive field presence, a portfolio of more than 150 products and a growing footprint across North India.

From General Therapies to a Focused Neuropsychiatric Portfolio

Wilwin Laboratories began its journey in the general pharmaceutical segment. Over time, however, Kumar’s direct exposure to the market influenced the company’s strategic direction. Rather than managing the business solely from the corporate office, he continued visiting doctors, prescribers and customers, using these interactions to identify evolving therapeutic requirements.

One area stood out - the growing need for products addressing neurological and mental-health conditions. This market understanding prompted Wilwin to progressively strengthen its presence in the neuro and psychiatric segments, which now account for approximately half of its portfolio.

Today, the company has a range of more than 150 products, with the remaining portfolio spread across general and other therapeutic categories, including cardiovascular-related therapies. Wilwin has also developed a presence in the de-addiction segment, including buprenorphine and combination products.

“The transition reflects a broader philosophy within the organisation: portfolio decisions should be guided by actual market requirements rather than expansion for its own sake. When relevant products emerge within its focus areas, Wilwin evaluates their potential and works to introduce suitable offerings to its markets”, speaks Sanjeev Kumar, Managing Director.

Quality Assurance Through Responsible Sourcing

For Wilwin, building credibility in pharmaceuticals begins with being clear about its role in the value chain. The company does not position itself as a manufacturer; instead, it sources pharmaceutical products from third-party manufacturing partners and markets them under its own trademarks. That model makes supplier selection and product verification particularly important. Wilwin follows a quality-focused sourcing approach and gets products tested through independent laboratories across India, maintaining test reports as part of its quality-assurance practices.

Such emphasis is becoming increasingly relevant as expectations around pharmaceutical quality and antibiotic stewardship intensify. The World Health Organization reported that around one in six laboratory-confirmed bacterial infections worldwide was resistant to antibiotics in 2023, highlighting the growing challenge of antimicrobial resistance and the importance of access to appropriate, quality-assured medicines.

For pharmaceutical marketers, therefore, sustainable growth depends not merely on expanding portfolios but on building reliable sourcing networks and maintaining confidence among prescribers and customers. Wilwin’s approach rests on working with dependable manufacturing partners, verifying product quality and maintaining close market relationships.

Combining Field Strength with Digital Visibility

While pharmaceutical businesses are increasingly adopting technology, Wilwin continues to view its field force as one of the strongest pillars of its operations. The company has a marketing team of approximately 50–60 professionals, supported by Kumar’s continued personal engagement with customers. Its footprint today extends across significant parts of North India, including Punjab, Haryana, Rajasthan, Himachal Pradesh and Delhi. Maintaining this network while ensuring strong customer relationships has been one of the company’s most demanding operational challenges.

For Kumar, scaling a pharmaceutical marketing business involves managing three interconnected priorities: maintaining an effective field force, consistently sourcing quality products from third-party manufacturers and sustaining relationships with customers. His response has been to remain close to the market, allowing customer feedback and field realities to influence business decisions.

Technology complements this traditional model. Digital platforms such as Google and IndiaMART have made Wilwin easier for prospective customers and partners to discover, extending the company’s visibility beyond conventional field interactions. The company sees the future as a combination of digital discoverability and relationship-led pharmaceutical marketing rather than one replacing the other.

Building the Next Phase Through Sustainable Growth

Wilwin’s progress is reflected in its financial trajectory as well. For FY2025–26, ending March 31, 2026, the company recorded annual sales of approximately INR 12 crore, a milestone that Kumar sees as an important marker in a longer growth journey. The next phase will remain anchored in measured expansion. “Wilwin plans to deepen its position in neuro and psychiatric therapies, evaluate opportunities across complementary therapeutic categories and progressively widen its geographical reach. Strengthening the field force, cultivating dependable third-party manufacturing relationships, maintaining product quality and remaining close to customers will continue to define its roadmap”, speaks Sanjeev Kumar.

As India’s pharmaceutical industry grows in scale and sophistication, businesses that combine specialised portfolios with reliable sourcing and strong market intelligence can occupy an important space in the value chain. For Wilwin Laboratories, the path forward is therefore less about chasing scale alone and more about building it deliberately - one market, one relationship and one quality-focused product at a time.